Indogulf Cropsci

- The company completed an IPO listing in early Q2 FY26, which resulted in fund induction. - Post-IPO, the company repaid an existing INR 40 crores loan using the IPO proceeds; currently, there is no term loan against the previous capex. - Current and upcoming capex of approximately INR 77 crores (including INR 63 crores already in CWIP and INR 14 crores for dry flowable plant) is being funded primarily through internal accruals and reserves. - No explicit mention of new fundraising planned through additional debt or equity beyond the recently completed IPO fundraising. - The management appears focused on utilizing the existing funds and cash flows for capacity expansion and operational growth in FY26 and FY27.

- Current and upcoming capex includes a dry flowable plant at Sonipat, Haryana, expected to be commissioned within FY26, costing around INR 14 crores. - An additional INR 63 crores capex is underway for expanding capacity, including the establishment of a fifth manufacturing unit. - Overall capex combining these is approximately INR 77 crores, aimed at increasing capacity by 50%-60%. - The new facility is expected to start operations by the end of FY26. - Payback period for this capex is estimated at 4 to 5 years at the EBITDA level. - Peak sales capacity post-expansion projected between INR 1,700 crores to INR 2,000 crores. - Capex is funded through internal reserves, bank loans (repaid via IPO proceeds), and IPO funds. - Strategic focus on capacity expansion supports top-line growth and margin improvement through better operational efficiency.

- The company is aspiring for 30% to 35% year-over-year revenue growth for FY26 and beyond, aiming for similar growth in FY27 and FY28. - Growth is driven by new product launches, geographic expansion, and increased penetration of the B2C segment, especially in Q2 and Q4. - New products launched recently contribute significantly; 9 products launched this year are expected to drive revenue growth. - B2C revenue is expected to grow, with INR 180-200 crores targeted in Q2 FY26. - Expansion of manufacturing capacity by 50-60% by fiscal end will support higher sales volumes and revenue. - Biologicals and nutrients segments are expected to see aggressive growth of 30-40%. - The new dry flowable plant is expected to enhance operational efficiency and competitiveness. - The company targets peak sales capacity of INR 1,700 to 2,000 crores with the expanded plants.

- FY26 revenue growth aspiration: 30% to 35% year-over-year, continuing similar trajectory in FY27 and FY28. - EBITDA margins expected to improve in percentage terms due to better operational efficiencies and a higher contribution from B2C and biological products. - Payback period for INR 77 crores capex expected within 4 to 5 years at EBITDA level. - Capacity expansion of 50% to 60% with utilization expected to remain similar, supporting revenue growth. - Profit before tax and exceptional items increased 509% YoY in Q1 FY26; profit after tax grew 187.4% YoY. - Emphasis on new product launches, multi-brand approach, and geographical expansion to drive growth. - Earnings growth driven by product mix improvements, cost discipline, and ramp-up of high-value segments such as biologicals and nutrients. - Operating profit margins historically range 10% to 11% annually; Q2 and Q4 quarters are the most profitable.

- The document does not explicitly provide current or expected order book or pending orders figures. - However, Q2 is noted as the highest utilization period due to a large number of orders and sales momentum, especially in B2C. - Capacity utilization averages 50% to 60%, rising in Q2 when order volumes peak. - The management is optimistic about revenue growth and efficiency improvements with new facilities coming online by the fiscal year-end. - Q2 sales are projected to be strong, with expected revenues around INR 300 crores, reflecting over 20-25% growth, implying a healthy order pipeline. - Expansion plans, including a 50-60% capacity increase by FY26 end, indicate expected order growth. - New product launches and market expansion are anticipated to drive order inflow consistently. In summary, while exact orderbook details are not disclosed, strong Q2 prospects and capacity expansions imply a robust pending order situation.